MOTS-c
Verdict card (component)
? Investigational
A 16-amino-acid mitochondrial-derived peptide encoded within the mitochondrial 12S rRNA gene, identified in 2015 as a regulator of metabolic homeostasis. MOTS-c (mitochondrial open reading frame of the twelve S rRNA-c) appears to act as a metabolic stress-response peptide — circulating levels rise with exercise, decline with age and metabolic disease, and the peptide regulates AMPK signaling, glucose homeostasis, and exercise capacity in animal models. Promoted in the longevity and biohacker space for exercise performance and metabolic health, but human clinical evidence is sparse and trials are early-stage.
Evidence signal row
- ✓ Strong preclinical evidence — animal models show metabolic and exercise benefits
- ! Limited human data — small Phase 1 studies; no Phase 2/3 efficacy trials
- ! Promoted ahead of evidence in longevity/biohacker contexts
Our verdict (3 sentences)
MOTS-c is a peptide whose biology is genuinely fascinating — a mitochondrial-encoded peptide that operates as a systemic metabolic regulator, the opposite direction of the typical “nuclear-genes-control-mitochondria” model. The animal data is consistent and the proposed mechanism (AMPK activation, GLUT4 translocation, exercise-mimetic effects) has plausible therapeutic relevance. What’s missing is meaningful human evidence at the doses and protocols used in gray-market practice — Phase 1 PK/safety work exists but Phase 2/3 efficacy trials in metabolic disease or exercise capacity have not read out.
Mechanism
MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial genome’s 12S rRNA region — a mitochondrial-derived peptide (MDP), part of an emerging class of peptides encoded by short open reading frames within mitochondrial RNA. The discovery (Lee et al, 2015) extended the textbook picture of mitochondrial gene products beyond the established 13 oxidative phosphorylation proteins.
Proposed mechanisms (still being characterized):
- AMPK activation — MOTS-c stimulates AMP-activated protein kinase, the cellular energy sensor. AMPK activation increases glucose uptake, fatty acid oxidation, and mitochondrial biogenesis.
- Folate cycle / one-carbon metabolism modulation — MOTS-c influences methionine cycle intermediates, with downstream effects on AMPK signaling
- GLUT4 translocation — increases skeletal muscle glucose uptake independent of insulin signaling
- Nuclear translocation under metabolic stress — MOTS-c can move to the nucleus and affect gene expression directly, extending its regulatory role beyond cytoplasm
Circulating MOTS-c levels are exercise-responsive (rise during and after exercise) and decline with age, obesity, and metabolic disease. This pattern positions MOTS-c as a potential exercise-mimetic and metabolic-protective signaling molecule.
The proposed pharmacological administration replicates this exercise-induced pulse, with the hypothesis that supplemental MOTS-c can restore metabolic flexibility in conditions where endogenous levels are reduced.
What the evidence shows
Discovery and animal preclinical (Lee et al, Cell Metab 2015): Foundational paper. Demonstrated MOTS-c regulates insulin sensitivity and metabolic homeostasis in mice. Subsequent animal studies have shown MOTS-c administration:
- Improves insulin sensitivity in diet-induced obesity models
- Increases exercise capacity and VO2 max in aged mice
- Reduces age-related muscle wasting
- Modulates body weight and adiposity
Human levels and exercise correlation: Multiple cross-sectional and exercise-intervention studies show:
- Circulating MOTS-c rises acutely with exercise
- Trained athletes have higher baseline levels than sedentary controls
- Levels decline with age and inversely correlate with insulin resistance markers
Human clinical trials:
- CB4211 (a MOTS-c peptide analog developed by CohBar) was tested in a Phase 1a/1b trial in patients with NAFLD — 20 obese participants with ≥10% liver fat. Results released by CohBar in 2021. Trial met its primary safety endpoint and showed preliminary efficacy in reducing liver fat content; further efficacy assessment was planned for Phase 2.
- CohBar has since dissolved as a company. The CB4211 / MOTS-c clinical development program is in indefinite limbo as of this review — no other commercial sponsor has publicly picked up the program.
- No completed Phase 2 efficacy trials in any indication.
The gap: Strong preclinical, real human Phase 1 safety and preliminary efficacy data on the CB4211 analog, but no Phase 2 efficacy data and no active commercial development. Academic research on native MOTS-c continues (e.g., 2025 work on pancreatic islet senescence, Nature-family journal), but translation to human clinical use is currently stalled. The biohacker enthusiasm runs well ahead of the clinical evidence — and ahead of the practical question of who, if anyone, will actually carry the molecule through Phase 2 and 3.
Dosing literature
There is no approved dose. Clinical-trial and gray-market protocols cite:
- Subcutaneous: 5–15 mg per dose, daily or 2–3 times per week
- Cycle structure: Variable; some protocols use continuous daily dosing for 8–12 weeks, others cycle with breaks
The Phase 1 trials used doses up to 25 mg subcutaneous; gray-market protocols generally stay lower. The biological rationale for any specific dose-frequency combination in healthy adults is not well-supported.
Risks and adverse events
In published clinical and gray-market use:
- Generally well-tolerated acute profile in Phase 1 dosing
- Injection site reactions
- Mild headache or fatigue
- Modest insulin sensitivity changes (typically beneficial direction, but could destabilize in patients with diabetes on insulin)
Theoretical concerns:
- Long-term effects are uncharacterized; the longest published exposures are weeks
- AMPK activation has multiple downstream effects — generally beneficial in metabolic disease contexts but theoretically could affect cell proliferation and other processes in ways relevant to long-term safety
- Mitochondrial peptide biology is still being understood — MOTS-c is one of several mitochondrial-derived peptides being characterized; the broader physiological context isn’t fully mapped
Quality concerns specific to gray-market product:
The 16-amino-acid sequence is straightforward to synthesize. However, MOTS-c has unusual stability characteristics — proteolytic degradation in plasma can be rapid, and formulation (storage temperature, reconstitution protocol) materially affects bioactivity. Mass-spec verification is uncommon in the gray-market channel; bioactivity verification is essentially non-existent.
Regulatory status
| Region | Status | Notes |
|---|---|---|
| United States | Not approved | CB4211 Phase 1a/1b in NAFLD met primary safety endpoint (CohBar 2021); CohBar has since dissolved |
| European Union | Not approved | |
| United Kingdom | Not approved | |
| All other markets | Not approved |
CohBar Inc. was the principal commercial developer of CB4211 (a MOTS-c analog). The company has since dissolved, leaving the clinical program without an active sponsor. Academic research on native MOTS-c continues; commercial translation is stalled.
Where to get it
There is no legitimate clinical access path currently. Gray-market peptide vendors sell “MOTS-c” products of variable quality.
We do not route readers to gray-market sources for MOTS-c. The biology is interesting; the evidence isn’t yet at a level that supports clinical use, and the gray-market quality picture is concerning given the molecule’s stability sensitivity. (See How we make money.)
References (selected)
- Lee C et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab 2015
Quick Facts
| Also Known As | MOTS-c, MOTS-c peptide, Mitochondrial-derived peptide MOTS-c |
|---|---|
| Sequence | MRWQEMGYIFYPRKLR |
| Molecular Formula | C101H152N28O22S2 |
| Molecular Weight | 2174.6 Da |
| PubChem CID | 146675088 |
Research Parameters
| Half-Life | Unknown in humans. Preliminary animal data suggests a relatively short plasma half-life, likely on the order of minutes to a few hours. |
|---|---|
| Stability | Lyophilized powder is stable for at least 24 months when stored at -20°C, protected from light and moisture. After reconstitution in bacteriostatic water, the solution should be stored at 2-8°C and is typically stable for up to 30 days. For long-term storage, aliquots of the reconstituted solution can be frozen at -20°C or -80°C. |
| Solubility | Bacteriostatic Water (0.9% Benzyl Alcohol) or Sterile Water for Injection. |
| Vial Size | 5 mg |
| Storage (Lyophilized) | -20°C, protect from light and moisture. For long-term storage, -80°C is recommended. |
| Storage (Reconstituted) | 2-8°C for short-term use (up to 30 days). For longer storage, aliquot and freeze at -20°C or -80°C. Avoid repeated freeze-thaw cycles. |
| Typical Research Dose | Not established for humans. Preclinical mouse studies use doses equivalent to approximately 10-100 mcg per mouse, translating to a wide range when scaled by weight. |
| Cycle Parameters | Not established for humans. In mouse research, common protocols involve daily or every-other-day intraperitoneal injections for periods of 4 to 16 weeks to study chronic metabolic effects. |
| Amino Acid Count | 16 |
Mechanism of Action
MOTS-c primarily functions as a regulator of metabolism and cellular stress response, shuttling between mitochondria and the nucleus. Its main mechanism involves the activation of the AMP-activated protein kinase (AMPK) pathway, a central cellular energy sensor.
AMPK Activation: MOTS-c treatment increases AMPK phosphorylation and activity in skeletal muscle and liver cells. This occurs independently of changes in the AMP/ATP ratio, suggesting a novel, direct mechanism of AMPK activation. Activated AMPK promotes catabolic processes like glucose uptake and fatty acid oxidation while inhibiting anabolic processes.
Nuclear Translocation and Gene Regulation: Under metabolic stress (e.g., glucose restriction, oxidative stress), MOTS-c translocates from mitochondria to the nucleus. In the nucleus, it interacts with transcriptional regulators and influences the expression of stress-responsive genes. A key target is the upregulation of nuclear-encoded genes involved in antioxidant defense, such as those regulated by the transcription factor Nrf2.
Inhibition of the Folate-Methionine Cycle: MOTS-c has been shown to inhibit the folate-methionine cycle by suppressing the enzyme AICAR transformylase/IMP cyclohydrolase (ATIC). This inhibition leads to an accumulation of AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), which in turn activates AMPK. This pathway links mitochondrial signaling to one-carbon metabolism and purine biosynthesis.
Insulin Sensitization: Through AMPK activation and potentially other pathways, MOTS-c enhances insulin sensitivity. It improves glucose uptake in skeletal muscle and reduces hepatic glucose production, contributing to improved systemic metabolic parameters.
Research Applications
Metabolic Syndrome and Insulin Resistance: Research in animal models demonstrates that MOTS-c administration improves insulin sensitivity, reduces diet-induced obesity, and enhances glucose homeostasis. It promotes glucose uptake in muscle and suppresses gluconeogenesis in the liver, making it a candidate for investigating treatments for type 2 diabetes and metabolic syndrome.
Aging and Longevity: MOTS-c is implicated in the biology of aging. Its levels decline with age, and exogenous administration in mice has been shown to improve physical performance and reduce age-dependent insulin resistance. It is considered a potential mediator of the benefits of exercise and caloric restriction, two well-known lifespan-extending interventions.
Exercise Mimetic and Muscle Function: Studies suggest MOTS-c may act as an exercise mimetic. Treatment improves exercise capacity and enhances metabolic fitness in mice, even without exercise. It promotes metabolic adaptation in skeletal muscle, increasing endurance and regulating fuel utilization.
Bone Metabolism: Emerging research indicates a role for MOTS-c in bone homeostasis. In vitro and preliminary animal studies suggest it may promote osteoblast differentiation and bone formation, while inhibiting osteoclastogenesis, pointing to potential applications in osteoporosis research.
Safety & Side Effects
The safety profile of MOTS-c in humans is unknown as no clinical trials have been completed. In animal studies (mice), no overt toxicity or significant adverse effects have been reported at the research doses used. Anecdotal reports from the research chemical community are extremely limited and not scientifically verified. Theoretical concerns are minimal given its endogenous nature, but potential immunogenicity with repeated administration or unforeseen off-target effects with chronic, high-dose use cannot be ruled out without formal toxicology studies.
Dosage Information
Disclaimer: The following information is derived solely from preclinical animal research. Human safety, efficacy, and dosing are not established.
In mouse studies, MOTS-c is typically administered via intraperitoneal (IP) injection. Common research doses range from 0.5 mg/kg to 5 mg/kg of body weight. It is often administered daily or every other day. Treatment durations in published studies vary from acute single injections to chronic administration over several weeks (e.g., 8-16 weeks) to assess long-term metabolic effects.
References
Lee, C., Zeng, J., Drew, B.G., et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism, 2015. 21(3): 443-454.
Ming, W., Lu, G., Xin, S., et al. Mitochondria related peptide MOTS-c suppresses ovariectomy-induced bone loss via AMPK activation. Biochemical and Biophysical Research Communications, 2016. 476(4): 412-419.
Reynolds, J.C., Lai, R.W., Woodhead, J.S.T., et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications, 2021. 12: 470.
Kim, K.H., Son, J.M., Benayoun, B.A., Lee, C. The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress. Cell Metabolism, 2018. 28(3): 516-524.e7.
Zempo, H., Kim, S.J., Fuku, N., et al. A pro-diabetogenic mtDNA polymorphism in the mitochondrial-derived peptide, MOTS-c. Aging, 2021. 13(2): 1692-1717.
Cobb, L.J., Lee, C., Xiao, J., et al. Naturally occurring mitochondrial-derived peptides are age-dependent regulators of apoptosis, insulin sensitivity, and inflammatory markers. Aging, 2016. 8(4): 796-809.